Rheumatoid Arthritis

RheumNow Podcast – ACR 20 is Coming to Town (10.30.20)

Save

Jack Cush, MD

Oct 29, 2020

Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com

Read Article

Vedolizumab Promising in Immune-Related GI Events

Save

Jack Cush, MD

Oct 27, 2020

Vedolizumab (Entyvio) was superior to infliximab (Remicade) for treating immune-mediated diarrhea and colitis (IMDC), a researcher reported.

In a retrospective study of patients with cancer, treatment with vedolizumab led to a 13% IMDC recurrence rate versus 28% with infliximab,

Read Article

Review of 127 pts w/ diagnostic criteria for palindromic rheumatism - Most affected JTS were wrist, knee, MCP; 34% later developed CTD (28% RA, 2% lupus 3% other CTD). Progression predicted by +RF (HR 2.9), PIP (HR 2.4), Wrist (HR 2.5) & female (HR 2.2)

Dr. John Cush RheumNow ( View Tweet)

Oct 26, 2020

Doctor computer laptop telemedicine telehealth

Telemedicine Outcomes in RA Care

Save

Jack Cush, MD

Oct 26, 2020

A new short‐term follow‐up study has shown no significant difference in outcomes and quality measures in patients with RA who were managed by telemedicine (compared to usual in-person care).

Read Article

PI facts: did you know that JAK inhibitors(UPA, Bari, Tofa) have a warning against use w/ severe liver problems. They have not been studied in pts w/ Hepatitis B or C.

Links:

https://bit.ly/35uHKGV

Dr. John Cush RheumNow ( View Tweet)

Oct 26, 2020

Listent to QD Clinics - A Podcast Weekly Compilation - Lessons from the clinic. Dr.

Links:

Dr. John Cush RheumNow ( View Tweet)

Oct 25, 2020

RheumNow Podcast – Back Talk: Questions from Listeners (10.23.20)

Save

Jack Cush, MD

Oct 23, 2020

Dr. Jack Cush reviews the news, journal reports, survey results and "Back Talk" questions from Rheums.

Read Article

Korea National Health databased looked at Fracture rates in RA patients taking TNFis, abatacept, or tocilizumab betw 2002 to 2016. They found no difference in Fx risk related to the biologic taken. https://t.co/W2dWWseXTc

Links:

https://bit.ly/2HcnyS7

Dr. John Cush RheumNow ( View Tweet)

Oct 22, 2020

Biologic Use for Arthritis Linked With Depression and Anxiety

Save

Jack Cush, MD

Oct 20, 2020

In a recent study of patients with inflammatory rheumatic diseases, the initiation of a biologic treatment or switching to another biologic was associated with an increased likelihood of the use of antidepressants and anxiolytics, reported Petros P. Sfikakis, MD, of the National and Kapodistrian

Read Article

Study of seropositivity in RA patients in the RISE (43,581) registry & Marketscan pts (1185) showed ICD10 Coding with M05 had a sensitivity = 0.73- 0.76, & PPV = 0.82 -0.84 for seropositive RA.

Links:

https://bit.ly/359hPUZ

Dr. John Cush RheumNow ( View Tweet)

Oct 20, 2020

SELECT CHOICE, H2H study of UPA vs ABA in TNF-IR RA pts; UPA had better DAS28-CRP & ABA had better Safety outcomes; Which would you use?

Dr. John Cush RheumNow ( View Tweet)

Oct 19, 2020

QD Clinics - Vignette Lessons from Rheum Clinic. Week 2: choosing IL-1 inhibitors, burnt out RA or not RA, trigger fingers, peripheral SpA, Gout or not?

Links:

Dr. John Cush RheumNow ( View Tweet)

Oct 19, 2020

TNF Inhibitors or non-TNF Biologics - First Best Choice?

Save

Jack Cush, MD

Oct 18, 2020

Prospective observational findings from the CORRONA registry of rheumatoid arthritis (RA) patients compared clinical outcomes between initial aggressive therapy using either a tumour necrosis factor inhibitor (TNFi) or a non-TNFi (biological disease-modifying antirheumatic drugs (bDMARDs) and

Read Article

RheumNow Podcast – Good Time Charlie…. (10.16.20)

Save

Jack Cush, MD

Oct 15, 2020

Dr. Jack Cush sings the news and journal reports from the past week on RheumNow.com.

Read Article

Juvenile localized scleroderma was Rx w/ MTX or MMF (in MTX refractory) and compared retrospectively. Facial linear scler. more likely in MTX pts and MMF pts had pansclerotic morphea or mixed subtype.

Links:

https://bit.ly/2GVzNCq

Dr. John Cush RheumNow ( View Tweet)

Oct 15, 2020

Abatacept vs. Upadacitinib in Biologic Refractory Rheumatoid Arthritis

Save

Jack Cush, MD

Oct 15, 2020

NEJM reports the results of the SELECT-Choice trial, a head to head study of upadacitinib (UPA) and abatacept (ABA) in biologic refractory rheumatoid arthritis (RA); 12 weeks results showed UPA was significantly more clinically effective than ABA using a DAS28-CRP remission, but ABA had fewer

Read Article

EUSTAR study of ILD in systemic sclerosis: 826 pts with SSc-ILD finds 27% with progressive ILD (mod-severe FVC decline >5-10%) over 12 mos. Predictive factors for FVC decline over 5 yrs were male sex, higher mRSS skin score and reflux/dysphagia symptoms.

Links:

https://bit.ly/3lVG53P

Dr. John Cush RheumNow ( View Tweet)

Oct 15, 2020

ICI Arthritis Tied to Cancer Progression

Save

Oct 14, 2020

Cancer patients treated with immune checkpoint inhibitors (ICI) who develop severe arthritis may be at risk for progression of the malignancy, a single-center study suggested.

Almost 90% of patients treated with ICI develop immune-related adverse events, which can include pulmonary,

Read Article

Tofacitinib and Thromboembolic Risk

Save

Jack Cush, MD

Oct 13, 2020

Mease and colleagues have reviewed the tofacitinib drug development and clinical trial data, finding the risk of venous (VTE) and arterial thromboembolism (ATE) to be low and augmented in patients with baseline cardiovascular abd VTE risk factors and those taking higher doses of tofacitinib (

Read Article

Study of 196 RA pts shows lung Dz common by chest CT, regardless of serostatus. RA lung=higher mortality (HR of 5.3). RA lung dz found in 28%; 16% had ILD, 14% bronchiectasis, 9.5% w pleural dz.

Links:

https://bit.ly/36Qm76a

Dr. John Cush RheumNow ( View Tweet)

Oct 12, 2020

Study of 5792 RA pts from 11 RCTs compared ACR Boolean remission with (4V) or without Pt Global scores (3V) using Xray & functional outcomes.

Links:

https://bit.ly/2GLP6gM

Dr. John Cush RheumNow ( View Tweet)

Oct 12, 2020

Thrombotic Risk in Rheumatoid Arthritis Linked to Disease Activity

Save

Jack Cush, MD

Oct 11, 2020

A large RA cohort study from the Swedish Rheumatology Quality Register shows a higher risk of venous thromboembolism (VTE) in rheumatoid arthritis (RA) and that risk is linked to RA disease activity.

Read Article

RheumNow Podcast – Bad Disease & Bad Outcomes (10.9.20)

Save

Jack Cush, MD

Oct 08, 2020

Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com.

Read Article

Study of 222 RA pts on MTX given anti-GMCSF (otilimab) 22·5 mg, 45 mg, 90 mg, 135 mg, 180 mg, or PBO weekly x 5 wks, then EOW. @wk 24 DAS28-CRP <2·6 5%, 16%. 19%, 14%, 14% respectively and 3% in PBO. Otilimab failed to meet primary endpoint.

Links:

https://bit.ly/3iDrecc

Dr. John Cush RheumNow ( View Tweet)

Oct 08, 2020

Lockdown worsening; UK survey 678 patients musculoskeletal diseases pts in late April 2020 shows 53% worsening of Sx; 1/3 had clinic/hosp access probs problems & most (88%) had no probs w/ getting meds; but 44% needed others to help them get meds.

Links: